AstraZeneca/Oxford say Covid vaccine shows 70% efficacy, can be 90% effective

"This vaccine's efficacy and safety confirm that it will be highly effective against Covid-19 and will have an immediate impact on this public health emergency," AstraZeneca chief executive Pascal Soriot said in a statement.

AstraZeneca said on Monday its vaccine for the novel coronavirus could be around 90% effective without any serious side effects, the latest drugmaker to unveil positive interim data in a scientific race to curb a global pandemic.

One dosing regimen shows vaccine efficacy of 90% when AZD1222 was given as half dose, followed by full dose at least a month apart. Second dosing regimen shows 62% efficacy when given two full doses at least a month apart. Combined analysis has average efficacy of 70%, said AstraZeneca

No serious safety events related to the vaccine have been confirmed and it was well tolerated across both dosing regimens, it said.


"This vaccine's efficacy and safety confirm that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency," Pascal Soriot, Astra's chief executive, said in a statement.

The Serum Institute of India has partnered with AstraZeneca to produce COVID-19 vaccine for global supply.

The British drugmaker's preliminary trial results mark a fresh breakthrough in the fight against a pandemic that has killed nearly 1.4 million people and roiled the global economy.
ADVERTISEMENT

British Prime minister Boris Johnson said it was "incredibly exciting news the Oxford vaccine has proved so effective in trials."

AstraZeneca shares fell 1.1% in early morning trade, defying expectations for a bounce and underperforming the wider market with the FTSE 100 index rising 0.5% at the open.

The interim analysis was based on 131 infections among participants who received the vaccine and those in a control group who were given an established meningitis shot.

The data showing a range of efficacy between 60% and 90% comes after U.S. rivals published interim data in recent weeks showing efficacy of more than 90%.
ADVERTISEMENT

While the efficacy reading from Astra's viral vector vaccine is lower than its U.S. rivals, the data will boost confidence about the chances of successfully developing a variety of vaccines using different approaches. Public health experts say the world will need many vaccines to meet global demand.

On Nov. 16, U.S.-based Moderna Inc said its experimental vaccine proved to be 94.5% effective based on an early data analysis.
ADVERTISEMENT

A week earlier, Pfizer Inc and Germany's BioNTech SE said their vaccine candidate had demonstrated greater than 90% efficacy that rose to 95% with analysis of full trial data.
Russia's Sputnik-V vaccine on Nov. 11 was also shown to be more than 90% effective, though only based on 20 infections.

The AstraZeneca vaccine uses a modified version of a chimpanzee common cold virus to deliver instructions to cells to fight the target virus, which is different than the new technology known as messenger RNA (mRNA) deployed by Pfizer/BioNTech and Moderna.

The company - one of the UK's most valuable listed companies - will now immediately prepare regulatory submission of the data to authorities around the world that have a framework in place for conditional or early approval.

It will also seek an emergency use listing from the World Health Organization to speed up availability in low-income countries. In parallel, the full analysis of the interim results is being submitted for publication in a peer-reviewed journal.
How the vaccine developed by Oxford University stacks up against Pfizer and Moderna
1/6

According to a report by AP, AstraZeneca said November 23 that late-stage trials showed its coronavirus vaccine was up to 90% effective, giving public health officials hope they may soon have access to a vaccine that is easier to distribute than some of its rivals. The results are based on interim analysis of trials in the U.K. and Brazil of a vaccine developed by Oxford University and manufactured by AstraZeneca. No hospitalizations or severe cases of COVID-19 were reported in those receiving the vaccine.

According to a report by AP, AstraZeneca said November 23 that late-stage trials showed its coronavirus vaccine was up to 90% effective, giving public health officials hope they may soon have access ..
Read More

AstraZeneca is the third major drug company to report late-stage results for its potential COVID-19 vaccine as the world anxiously waits for vaccines that will end the pandemic that has killed almost 1.4 million people. Pfizer and Moderna last week reported preliminary results from late-stage trials showing their vaccines were almost 95% effective.

AstraZeneca is the third major drug company to report late-stage results for its potential COVID-19 vaccine as the world anxiously waits for vaccines that will end the pandemic that has killed almost..
Read More

Unlike the Pfizer and Moderna vaccines, the Oxford-AstraZeneca candidate doesn't have to be stored at ultra-cold temperatures, making it easier to distribute, especially in developing countries. All three vaccines must be approved by regulators before they can be widely distributed.

Unlike the Pfizer and Moderna vaccines, the Oxford-AstraZeneca candidate doesn't have to be stored at ultra-cold temperatures, making it easier to distribute, especially in developing countries. All ..
Read More

AstraZeneca said it will immediately apply for early approval of the vaccine where possible, and it will seek an emergency use listing from the World Health Organization, so it can make the vaccine available in low-income countries.

AstraZeneca said it will immediately apply for early approval of the vaccine where possible, and it will seek an emergency use listing from the World Health Organization, so it can make the vaccine a..
Read More

The AstraZeneca trial looked at two different dosing regimens. A half-dose of the vaccine followed by a full dose at least one month later was 90% effective. Another approach, giving patients two full doses one month apart, was 62% effective. The combined results showed an average efficacy rate of 70%.

The AstraZeneca trial looked at two different dosing regimens. A half-dose of the vaccine followed by a full dose at least one month later was 90% effective. Another approach, giving patients two ful..
Read More

The vaccine uses a weakened version of a common cold virus that is combined with genetic material for the characteristic spike protein of the virus that causes COVID-19. After vaccination, the spike protein primes the immune system to attack the virus if it later infects the body.

The vaccine uses a weakened version of a common cold virus that is combined with genetic material for the characteristic spike protein of the virus that causes COVID-19. After vaccination, the spike ..
Read More

READ MORE
ADVERTISEMENT

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

Related Companies

More from our Partners

Loading next story
Text Size:AAA
Success
This article has been saved

*

+